MTOR and hepatocellular carcinoma: To the best of our knowledge, our study was the first study to investigate the combination of matrine and mTOR inhibitor KU0063794 to improve the antigen presentation ability of DCs and the antitumor efficacy of DC vaccine for HCC patients.